These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39104176)

  • 1. Targeted degradation of KRAS protein in non-small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles.
    Wang X; Su L; Niu C; Li X; Wang R; Li B; Liu S; Xu Y
    Drug Dev Res; 2024 Aug; 85(5):e22241. PubMed ID: 39104176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and validation of a sensitive LC-MS/MS method for the quantification of KRAS
    Wang Y; Wang Z; Wang X; Li X; Liu X; Zhang X; Liu S
    Biomed Chromatogr; 2023 Jun; 37(6):e5629. PubMed ID: 36945141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cell penetrating peptides enhance intracellular translocation and function of siRNA encapsulated in Pegylated liposomes].
    Wang W; Tang N; Zhang CL; Liu XJ; Hu H; Zhang ZX; Liang W
    Yao Xue Xue Bao; 2006 Feb; 41(2):142-8. PubMed ID: 16671545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.
    Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X
    Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer.
    Liu J; Xue L; Xu X; Luo J; Zhang S
    Exp Cell Res; 2021 Nov; 408(2):112868. PubMed ID: 34648846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
    Biswas S; Dodwadkar NS; Deshpande PP; Parab S; Torchilin VP
    Eur J Pharm Biopharm; 2013 Aug; 84(3):517-25. PubMed ID: 23333899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC.
    Kong L; Zhang SM; Chu JH; Liu XZ; Zhang L; He SY; Yang SM; Ju RJ; Li XT
    Int J Nanomedicine; 2020; 15():6451-6468. PubMed ID: 32922011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of R
    Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
    Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
    J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of PROTACS degrading KRAS and SOS1.
    Hamilton G; Eggerstorfer MT; Stickler S
    Oncol Res; 2024; 32(8):1257-1264. PubMed ID: 39055890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of KRAS
    Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
    Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
    Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
    Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.
    Biswas S; Deshpande PP; Perche F; Dodwadkar NS; Sane SD; Torchilin VP
    Cancer Lett; 2013 Jul; 335(1):191-200. PubMed ID: 23419527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
    Gao H; Zhang Q; Yang Y; Jiang X; He Q
    Int J Pharm; 2015 Jan; 478(1):240-250. PubMed ID: 25448586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
    Riaz MK; Zhang X; Wong KH; Chen H; Liu Q; Chen X; Zhang G; Lu A; Yang Z
    Int J Nanomedicine; 2019; 14():2879-2902. PubMed ID: 31118613
    [No Abstract]   [Full Text] [Related]  

  • 17. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
    Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
    Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis targeting chimeras in non-small cell lung cancer.
    Hagopian G; Grant C; Nagasaka M
    Cancer Treat Rev; 2023 Jun; 117():102561. PubMed ID: 37178629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC).
    Zhang J; Chen X; Chen C; Li F; Song X; Liu C; Liao K; Su MY; Tan CSH; Fang L; Rao H
    J Med Chem; 2024 Aug; 67(16):13666-13680. PubMed ID: 39114932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.